8-K filing — Prelude Therapeutics Inc (PRLD)
Filed: 2026-09-10 AccNo: 0001193125-26-387232 Size: 20 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12
JP Morgan analyst Joyce Zhou initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Overweight rating and announces Price Target of $12.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Prelude Therapeutics Receives FDA Clearance To Proceed With A Phase 1 Study Under Its Investigational New Drug Application For PRT13722 For The Treatment Of Patients With HR+/HER2- Breast Cancer; Expects To Begin Enrolling Patients In Q4 2026
"Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations," stated Charles Morris, MBChB, MRCP, Chief Medical Officer
Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.